HDM2017
HDM2017 is an experimental investigational agent whose form is not stated in the registry from Hangzhou Zhongmei Huadong Pharmaceutical in phase 2 trials for colorectal cancer, aimed at MET.
Overview
HDM2017 is an investigational agent whose form is not stated in the registry developed by Hangzhou Zhongmei Huadong Pharmaceutical. Its target is MET. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in colorectal cancer. The largest, NCT07805551, plans to enrol 220 participants with primary completion expected 2030-08. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Latest papers
topQuery for this drug: (TITLE:"HDM2017" OR ABSTRACT:"HDM2017") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about HDM2017, not a curated reading list.
Similar pages
not linked directly; found by shared links- TreatmentTQB2922
Shares MET, Colorectal cancer and the tags pipeline, ctgov-ingest.
- TreatmentJS111
Shares MET and the tags pipeline, ctgov-ingest.
- TreatmentBotensilimab
Shares Colorectal cancer and the tags pipeline, ctgov-ingest.
- TreatmentTQB6411
Shares MET and the tags pipeline, ctgov-ingest.
- TreatmentMCLA-129
Shares MET, Colorectal cancer and the tags pipeline, ctgov-ingest.
- TreatmentABT-301
Shares Colorectal cancer and the tags pipeline, ctgov-ingest.
- TreatmentJYP0015
Shares Colorectal cancer and the tags pipeline, ctgov-ingest.
- TreatmentGRT-C901
Shares Colorectal cancer and the tags pipeline, ctgov-ingest.